Cingulate Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Cingulate is gedaald met een gemiddeld jaarlijks tempo van -18.6%, terwijl de winst van de sector Pharmaceuticals jaarlijks afnam met 0.2%.

Belangrijke informatie

-18.6%

Groei van de winst

51.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-619.2%
Nettomarge	n/a
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Aug 26

Cingulate Q2 GAAP EPS of -$0.36

Aug 11

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Apr 04

Opbrengsten en kosten

Hoe Cingulate geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqCM:CING Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven
30 Jun 24	-19	6
31 Mar 24	-23	7
31 Dec 23	-24	7
30 Sep 23	-21	8
30 Jun 23	-19	8
31 Mar 23	-17	8
31 Dec 22	-18	9
30 Sep 22	-16	7
30 Jun 22	-27	7
31 Mar 22	-24	6
31 Dec 21	-21	4
30 Sep 21	-19	3
30 Jun 21	-5	2
31 Mar 21	-6	2
31 Dec 20	-7	2

Kwaliteitswinsten: CING is momenteel verliesgevend.

Groeiende winstmarge: CING is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CING is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 18.6% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CING over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CING is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 12.4% ).

Rendement op eigen vermogen

Hoge ROE: CING heeft een negatief Return on Equity ( -619.24% ), omdat het momenteel verliesgevend is.

Cingulate Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

The Nasdaq Hearings Panel Grants Cingulate's Request for an Exception to Demonstrate Compliance with the $1.00 Minimum Bid Price Requirement Set in Nasdaq Listing Rule 5550(a)(2) for Continued Listing Through August 23, 2024

Cingulate Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on The Nasdaq Capital Market

Cingulate Inc., Annual General Meeting, Jun 11, 2024

Cingulate Inc. Regains Compliance with the Board Composition Requirements of Nasdaq Set in Nasdaq Listing Rule 5605

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

Cingulate Inc. Announces Promotion of Jennifer Callahan as Chief Financial Officer

Cingulate Inc. has filed a Follow-on Equity Offering in the amount of $26 million.

Cingulate Receives Non-Compliance Notice from Nasdaq

Cingulate Inc. and Cingulate Therapeutics LLC Announce Resignation of Officer

Scott Applebaum Provides Cingulate Inc. with Notice of His Resignation from the Board of Directors

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTX-2103 (Buspirone)

Cingulate Inc. has filed a Follow-on Equity Offering.

The Listing Qualifications Staff of The Nasdaq Stock Market LLC Determines to Delist Cingulate's Securities from Nasdaq Unless it Timely Requests Hearing Before the Nasdaq Hearings Panel

Cingulate Inc. to Host CNS Key Opinion Leader Panel in New York City Expert Analysis of Cingulate, it’s Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations

Cingulate Weighs Reverse Stock Split to Avoid Delisting

Cingulate Inc. has completed a Follow-on Equity Offering in the amount of $4 million.

New major risk - Shareholder dilution

New major risk - Negative shareholders equity

Cingulate Inc. Receives A Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Cingulate Inc. Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for Adhd

Cingulate Inc. Successfully Manufactures Clinical Supply Initiation of Pediatric Phase 3 Studies to Commence in July and August

New major risk - Market cap size

Cingulate Completes Phase 3 Adult Trial of Ctx-1301 (Dexmethylphenidate) for Adhd

Cingulate Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

Cingulate Inc., Annual General Meeting, Jun 15, 2023

Forecast to breakeven in 2025

No longer forecast to breakeven

Cingulate Inc. Announces Resignation of Jeff Conroy from the Board of Directors

Cingulate Inc. Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Independent Director recently bought US$75k worth of stock

Cingulate Inc. Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD

Cingulate Inc. Provides Clinical Update

Cingulate Inc. Announces the Resignation of Jeff Hargroves from the Board of Directors

Cingulate Presents Data for its Triple-Release Buspirone Product Candidate: CTx-2103

Here's Why We're A Bit Worried About Cingulate's (NASDAQ:CING) Cash Burn Situation

Cingulate Inc. Appoints Scott Applebaum as Class III Director

Cingulate Q2 GAAP EPS of -$0.36

Cingulate Inc. Announces Completion of CTx-2103 Human Formulation Study for the Treatment of Anxiety Disorders

Cingulate Inc. Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Disorders

Cingulate Inc. Announces First Subject Dosing in its Human Formulation Study of CTX-2103 (Buspirone) for the Treatment of Anxiety

Cingulate Inc., Annual General Meeting, Jun 08, 2022

Is Cingulate (NASDAQ:CING) In A Good Position To Deliver On Growth Plans?

Independent Director recently bought US$89k worth of stock

Cingulate Inc Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for Attention Deficit/Hyperactivity Disorder (ADHD)

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden